IL10
Interleukin-10
Also known as: CSIF, IL-10, IL10_HUMAN, IL10A, TGIF
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P22301
- Gene
- IL10
- Ensembl
- ENSG00000136634
- Chromosome
- 1
- Canonical length
- 178 aa
- Protein class
- Cancer-related genes, Candidate cardiovascular disease genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins
- Secretome location
- Secreted to blood
- Quaternary structure
- Homodimer
OverviewNCBI Gene
The protein encoded by this gene is a cytokine produced primarily by monocytes and to a lesser extent by lymphocytes. This cytokine has pleiotropic effects in immunoregulation and inflammation. It down-regulates the expression of Th1 cytokines, MHC class II Ags, and costimulatory molecules on macrophages. It also enhances B cell survival, proliferation, and antibody production. This cytokine can block NF-kappa B activity, and is involved in the regulation of the JAK-STAT signaling pathway. Knockout studies in mice suggested the function of this cytokine as an essential immunoregulator in the intestinal tract. Mutations in this gene are associated with an increased susceptibility to HIV-1 infection and rheumatoid arthritis. [provided by RefSeq, May 2020]
Canonical amino-acid sequenceUniProt
178 residues, UniProt reviewed canonical sequence.
>P22301|IL10
1 MHSSALLCCL VLLTGVRASP GQGTQSENSC THFPGNLPNM LRDLRDAFSR VKTFFQMKDQ
61 LDNLLLKESL LEDFKGYLGC QALSEMIQFY LEEVMPQAEN QDPDIKAHVN SLGENLKTLR
121 LRLRRCHRFL PCENKSKAVE QVKNAFNKLQ EKGIYKAMSE FDIFINYIEA YMTMKIRNLocalizationUniProt · AlphaFold · HPA
Whether an antibody against IL10 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.45
- Highest tissue expression
- 6.5 nTPM
Expression across tissuesHPA
Tissue
- appendix: 6.5 nTPM
- spleen: 6.1 nTPM
- adipose tissue: 5.5 nTPM
- lymph node: 4.8 nTPM
- gallbladder: 3 nTPM
- bone marrow: 2.9 nTPM
Single-cell type
- monocytes: 258 nCPM
- macrophages: 95 nCPM
- kupffer cells: 57 nCPM
- hofbauer cells: 31 nCPM
- cdc: 25 nCPM
- thymocytes: 11 nCPM
Immune cell
- classical monocyte: 1.6 nTPM
- intermediate monocyte: 1.3 nTPM
- non-classical monocyte: 0.5 nTPM
- T-reg: 0.3 nTPM
- total PBMC: 0.3 nTPM
- memory CD8 T-cell: 0.2 nTPM
Brain region
- thalamus: 5.7 nTPM
- white matter: 1.7 nTPM
- choroid plexus: 1.6 nTPM
- medulla oblongata: 1.3 nTPM
- pons: 1.2 nTPM
- hypothalamus: 1.1 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about IL10.
Disease | GeneticClinVar
2 pathogenic / likely-pathogenic of 144 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Rheumatoid arthritis, progression of
- Leprosy, susceptibility to, 1
- Hepatitis C virus, susceptibility to
Disease | AutoantibodyPubMed
Conditions in which antibodies against IL10 are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for IL10 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
38 publications
- Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice.
1994 · J Exp Med · RCR 10.8 · 474 citations - Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus.
1995 · J Exp Med · RCR 10.4 · 472 citations - Neutralizing Autoantibodies against Interleukin-10 in Inflammatory Bowel Disease.
2024 · N Engl J Med · RCR 5.2 · 37 citations - Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand.
1997 · J Clin Invest · RCR 2.9 · 141 citations - Development of an animal model of autoimmune thyroid eye disease.
1999 · J Immunol · RCR 2.3 · 92 citations
Show 20 more of 38 total
- Interleukin-10 (IL-10) secretion in systemic lupus erythematosus and rheumatoid arthritis: IL-10-dependent CD4+CD45RO+ T cell-B cell antibody synthesis.
1996 · J Clin Immunol · RCR 1.5 · 62 citations - Functional analysis of rheumatoid factor-producing B cells from the synovial fluid of rheumatoid arthritis patients.
1998 · Arthritis Rheum · RCR 1.1 · 48 citations - Interleukin 10 hampers endothelial cell differentiation and enhances the effects of interferon α on lupus endothelial cell progenitors.
2015 · Rheumatology (Oxford) · RCR 1 · 26 citations - Activation of formyl peptide receptor 1 elicits therapeutic effects against collagen-induced arthritis.
2021 · J Cell Mol Med · RCR 0.9 · 12 citations - Effect of neutralizing antibodies to IL-10 and C5 on the renal damage caused by a pathogenic human anti-dsDNA antibody.
2004 · Rheumatology (Oxford) · RCR 0.9 · 41 citations - Tolerogenic Dendritic Cells Attenuate Experimental Autoimmune Antimyeloperoxidase Glomerulonephritis.
2019 · J Am Soc Nephrol · RCR 0.8 · 19 citations - Prevention of diabetes in NOD mice by a mutated I-Ab transgene.
1998 · Diabetes · RCR 0.7 · 42 citations - Patients with inflammatory bowel disease may have a transforming growth factor-beta-, interleukin (IL)-2- or IL-10-deficient state induced by intrinsic neutralizing antibodies.
2009 · Clin Exp Immunol · RCR 0.7 · 31 citations - Analysis of the T cells that are potentially involved in autoantibody production in pemphigus vulgaris.
1999 · J Dermatol · RCR 0.7 · 24 citations - Interleukin-10 promotes anti-collagen antibody production in type I diabetic peripheral B lymphocytes.
1997 · J Periodontal Res · RCR 0.7 · 20 citations - Identification of human IgG autoantibodies specific for IL-10.
1996 · Clin Exp Immunol · RCR 0.6 · 24 citations - Systemic lupus erythematosus monocytes are less responsive to interleukin-10 in the presence of immune complexes.
2011 · Arthritis Rheum · RCR 0.6 · 23 citations - IL-10-specific autoantibodies predict major adverse cardiovascular events in kidney transplanted patients - a retrospective cohort study.
2019 · Transpl Int · RCR 0.5 · 10 citations - Natural IgM anti-leucocyte autoantibodies (IgM-ALA) regulate inflammation induced by innate and adaptive immune mechanisms.
2014 · J Clin Immunol · RCR 0.5 · 14 citations - Anti-IL-10 antibody in systemic lupus erythematosus.
2019 · Open Access Rheumatol · RCR 0.4 · 10 citations - Activation and differentiation of autoreactive B-1 cells by interleukin 10 induce autoimmune hemolytic anemia in Fas-deficient antierythrocyte immunoglobulin transgenic mice.
2002 · J Exp Med · RCR 0.4 · 27 citations - Enhancement of IL-10 bioactivity using an IL-10 peptide-based vaccine exacerbates Leishmania major infection and improves airway inflammation in mice.
2010 · Vaccine · RCR 0.4 · 14 citations - Elevated IL-10 inhibits GM-CSF synthesis in pulmonary alveolar proteinosis.
2003 · Autoimmunity · RCR 0.3 · 14 citations - Autoantibody production in healthy elderly people is not promoted by interleukin-10 although this cytokine is expressed in them by a peculiar CD8+CD3+ large granular cell subpopulation.
1997 · Scand J Immunol · RCR 0.3 · 13 citations - Involvement of IL-10 in induction of autoimmune hemolytic anemia in anti-erythrocyte Ig transgenic mice.
1998 · Int Immunol · RCR 0.3 · 19 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.04
- gnomAD pLI
- 0.01
- gnomAD missense Z
- 0.84
- DepMap mean gene effect
- 0.06
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- B cell differentiation
- B cell proliferation
- branching involved in labyrinthine layer morphogenesis
- cellular response to estradiol stimulus
- cellular response to hepatocyte growth factor stimulus
- cellular response to lipopolysaccharide
- chronic inflammatory response to antigenic stimulus
- defense response to bacterium
- defense response to protozoan
- endothelial cell apoptotic process
- hemopoiesis
- immune response
- interleukin-10-mediated signaling pathway
- leukocyte chemotaxis
- liver regeneration
- negative regulation of apoptotic process
- negative regulation of autophagy
- negative regulation of B cell proliferation
- negative regulation of cell population proliferation
- negative regulation of chemokine (C-C motif) ligand 5 production
- negative regulation of cytokine production
- negative regulation of cytokine production involved in immune response
- negative regulation of heterotypic cell-cell adhesion
- negative regulation of inflammatory response
- negative regulation of interferon-alpha production
- negative regulation of interleukin-1 production
- negative regulation of interleukin-12 production
- negative regulation of interleukin-18 production
- negative regulation of interleukin-6 production
- negative regulation of interleukin-8 production
- negative regulation of membrane protein ectodomain proteolysis
- negative regulation of MHC class II biosynthetic process
- negative regulation of mitotic cell cycle
- negative regulation of myeloid dendritic cell activation
- negative regulation of nitric oxide biosynthetic process
- negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway
- negative regulation of T cell proliferation
- negative regulation of tumor necrosis factor production
- negative regulation of type II interferon production
- negative regulation of vascular associated smooth muscle cell proliferation
- positive regulation of B cell apoptotic process
- positive regulation of cell cycle
- positive regulation of cytokine production
- positive regulation of DNA-templated transcription
- positive regulation of endothelial cell proliferation
- positive regulation of heterotypic cell-cell adhesion
- positive regulation of immunoglobulin production
- positive regulation of macrophage activation
- positive regulation of MHC class II biosynthetic process
- positive regulation of miRNA transcription
- positive regulation of plasma cell differentiation
- positive regulation of receptor signaling pathway via JAK-STAT
- positive regulation of sprouting angiogenesis
- positive regulation of transcription by RNA polymerase II
- positive regulation of vascular associated smooth muscle cell proliferation
- regulation of gene expression
- regulation of isotype switching
- regulation of synapse organization
- response to activity
- response to carbon monoxide
- response to glucocorticoid
- response to inactivity
- response to insulin
- response to molecule of bacterial origin
- response to xenobiotic stimulus
- type 2 immune response
- negative regulation of chronic inflammatory response to antigenic stimulus
- negative regulation of cytokine activity
- regulation of response to wounding
Molecular functions
- cytokine activity
- growth factor activity
- protein dimerization activity
- interleukin-10 receptor binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of IL10 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads IL10 as an antibody target. Whether an autoantibody or antibody against IL10 could matter depends on whether native IL10 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
IL10 is annotated as secreted, so native IL10 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Source-annotated serology context
The source annotations explicitly mention antibody, autoantibody, autoantigen, or autoimmune context. This is biological context, not study-specific reactivity.
- It also enhances B cell survival, proliferation, and antibody production.
Loading the interactive Seroatlas protein explorer...